Abstract library

20 results for "Prinzi".
#885 The Role of Combined 68Ga-DOTATOC and 18F-FDG PET/CT in Patients with Pancreatic Neuroendocrine Tumors
Introduction: The value of combined (68)Ga-DOTATOC (68Ga) and (18)F-FDG (18FDG) PET/CT in diagnosis and staging of pancreatic NET is still unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Stefano Partelli
#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors
Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Francesco Panzuto
#955 Usefulness of the WHO Classification and of the ENETS TNM Staging System to Predict Prognosis in Patients with Rectal NENs
Introduction: WHO classification and TNM staging system have been proposed for rectal neuroendocrine neoplasia (NENs). However, their prognostic accuracy is not validated yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Gianfranco Delle Fave
#1088 Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up
Introduction: Digestive Neuroendocrine Neoplasms (DNENs) express in 80% of cases somatostatin receptors (SSTRs) detected by functional imaging tests (FITs). FITs are needed at diagnosis to define therapy but their role in follow-up (FU) is unclear
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Elettra Merola
Authors: Merola E, Panzuto F, Capurso G, Kump P, ...
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#1232 Prognostic Role of FDG-PET in Advanced Digestive Neuroendocrine Neoplasms
Introduction: The role of FDG-PET to predict clinical outcome in advanced digestive neuroendocrine neoplasms (dNENs) is still unclear
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Doctor Maria Rinzivillo
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto
#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Francesco Panzuto
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.